Story perspectives

Supreme Court to Hear Key Patent Case Impacting Generic Drugs

1/17/2026

47 4

Summary

Story summary

The U.S. Supreme Court will hear a patent dispute involving Amarin Pharma's Vascepa, potentially affecting generic makers and skinny labels.
Amarin sued Hikma, a British generic drug maker, for allegedly encouraging doctors to prescribe Hikma's generic in ways that infringe Amarin's patent rights.
A Federal Circuit ruling revived the case after a lower court dismissal.
Hikma's appeal is supported by the Trump administration, highlighting potential implications for affordable medications.

1 of 1

Story summary

The U.S. Supreme Court will hear a patent dispute involving Amarin Pharma's Vascepa, potentially affecting generic makers and skinny labels.
Amarin sued Hikma, a British generic drug maker, for allegedly encouraging doctors to prescribe Hikma's generic in ways that infringe Amarin's patent rights.
A Federal Circuit ruling revived the case after a lower court dismissal.
Hikma's appeal is supported by the Trump administration, highlighting potential implications for affordable medications.